Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies

Pediatric Blood and Cancer

Volumn 55, Issue 6, 2010, Pages 1145-1152

  Schellong, Günther ^a   Riepenhausen, Marianne ^a   Bruch, Christian ^b   Kotthoff, Stefan ^a   Vogt, Johannes ^a   Bölling, Tobias ^a   Dieckmann, Karin ^c   Pötter, Richard ^c   Heinecke, Achim ^a   Brämswig, Jürgen ^a   Dörffel, Wolfgang ^d  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b St Josef Hospital Zell   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Public Health Department Steglitz Zehlendorf   (Germany)

Author keywords

Cardiac late effects; Hodgkin disease; Long term follow up; Mediastinal radiotherapy; Radiation dose; Valvular defects

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADOLESCENT DISEASE; AORTA VALVE DISEASE; ARTICLE; AUSTRALIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVOR; CARDIOMYOPATHY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GERMANY; HEART DISEASE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HODGKIN DISEASE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MITRAL VALVE DISEASE; MULTIPLE CYCLE TREATMENT; PERICARDIAL DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY VALVE DISEASE; QUESTIONNAIRE; RADIATION DOSE; RISK ASSESSMENT; TRICUSPID VALVE DISEASE; VALVULAR HEART DISEASE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HEART VALVE DISEASES; HODGKIN DISEASE; HUMANS; LONGITUDINAL STUDIES; MALE; MEDIASTINAL NEOPLASMS; PREDNISONE; PROCARBAZINE; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 77958559758     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22664     Document Type: Article

References (34)

1. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: A prospective longitudinal study. Cancer 2003; 97: 1991-1998.
2. Adams MJ, Hardenbergh PH, Constine LS, et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003; 45: 55-75.
3. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993; 11: 1208-1215.
4. Glanzmann C, Kaufmann P, Jenni R, et al. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 1998; 46: 51-62.
5. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109: 1878-1886.
6. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949-1955.
7. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst 2007; 99: 206-214.
8. Lund MB, Ihlen H, Voss BM, et al. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: An echocardiographic study. Heart 1996; 75: 591-595.
9. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290: 2831-2837.
10. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003; 42: 743-749.
11. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139-3148.
12. Bramswig JH, Hörnig-Franz I, Riepenhausen M, et al. The challenge of pediatric Hodgkin's disease: Where is the balance between cure and long-term toxicity? A report of the West German multicenter studies DAL-HD-78, DAL-HD-82 and DAL-HD-85. Leuk Lymphoma 1990; 3: 183-193.
13. Schellong G. Treatment of children and adolescents with Hodgkin's disease: The experience of the German-Austrian Paediatric Study Group. Baillieres Clin Haematol 1996; 9: 619-634.
14. Schellong G, Hornig-Franz I, Rath B, et al. Reducing radiation dosage to 20-30 Gy in combined chemo-/radiotherapy of Hodgkin's disease in childhood. A report of the cooperative DAL-HD-87 therapy study. Klin Padiatr 1994; 206: 253-262.
15. Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999; 17: 3736-3744.
16. Bramswig JH, Heimes U, Heiermann E, et al. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 1990; 65: 1298-1302.
17. Schellong G. The balance between cure and late effects in childhood Hodgkin's lymphoma: The experience of the German-Austrian Study-Group since 1978. German-Austrian Pediatric Hodgkin's Disease Study Group. Ann Oncol 1996; 7: 67-72.
18. Schellong G, Riepenhausen M, Creutzig U, et al. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group. J Clin Oncol 1997; 15: 2247-2253.
19. Gerres L, Bramswig JH, Schlegel W, et al. The effects of etoposide on testicular function in boys treated for Hodgkin's disease. Cancer 1998; 83: 2217-2222.
20. Schellong G, Riepenhausen M. Late effects after therapy of Hodgkin's disease: Update 2003/04 on overwhelming post-splenectomy infections and secondary malignancies. Klin Padiatr 2004; 216: 364-369.
21. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861.
22. Kaplan HS. Hodgkin's disease. Cambridge: Harvard University Press; 1980.
23. Potter R, Dieckmann K, Hofmann J, et al. Individualisation of radiation fields based on modern sectional imaging within combination treatment of pediatric Hodgkin's Disease (HD): Evaluation of 386 patients from the German-Austrian multicentre trial (HD-90). Int J Radiat Oncol Biol Phys 1995; 32: 181.
24. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Developed in collaboration with the Society of Cardiovascular Anesthesiologists: Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006; 114: e84-e231.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
26. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
27. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
28. Cox DR. Regression models and life-tables. J R Stat Soc Ser B (Methodological) 1972; 34: 187-220.
29. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-Results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000; 18: 1500-1507.
30. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20: 3765-3771.
31. Dorffel W, Luders H, Ruhl U, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Padiatr 2003; 215: 139-145.
32. Chow LM, Nathan PC, Hodgson DC, et al. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol 2006; 24: 5735-5741.
33. Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007; 25: 332-337.
34. Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008; 121: e387-e396.